Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Sosial dan Sains Journal Medical Informatics Technology
Rananda, Arif
Unknown Affiliation
Astronomy Computer Science & IT Dentistry Engineering Environmental Science Law, Crime, Criminology & Criminal Justice Library & Information Science Medicine & Pharmacology Physics Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Low Tuberculosis Screening among Household Family Members of Tuberculosis Patients in Banyuarang and Sidowarek Farid, Muhammad Rifqo Hafidzudin; Rananda, Arif; Aflahudin, Muhammad Ahda Naufal; Musalim, Dian Anggraini Permatasari; Hariftyani, Arisvia Sukma; Hanani, Nadya Kelfinta; Rofiq, Rodia Amanata; Aulia, Shazia Hafazhah; Sidqoh, Aida Badi’atus; Hewiz, Alya Shafira
Journal Medical Informatics Technology Volume 1 No. 4, December 2023
Publisher : SAFE-Network

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37034/medinftech.v1i4.19

Abstract

Early tuberculosis detection is vital, necessitating widespread screening. The WHO's End Tuberculosis strategy aims to combat this epidemic. Active screening is critical for identifying asymptomatic individuals at risk. Data from Pulorejo Primary Health Center, Jombang, indicates a low 10% coverage of suspected cases in 2021, particularly among household contacts, resulting in continued transmission, late detection, post-treatment symptoms, and even death. Therefore, this study was conducted to determine the number of screening participation of households of tuberculosis patients in Banyuarang and Sidowarek Village. This research is a descriptive observational. The data collected was primary data from questionnaires. The study population consisted of households of tuberculosis patients in the Banyuarang and Sidowarek Villages, Jombang Regency. Data collected from 12 respondents showed the prevalent characteristics among the 12 respondents were predominantly female, adult age, high school education, working, limited knowledge about tuberculosis, and easy access to healthcare services. Among the 12 respondents in Banyuarang and Sidowarek, 9 respondents had never been screened, while 3 respondents had undergone screening. The primary reasons for respondents not undergoing screening were lack of awareness regarding the necessity of screening and busy schedules.
Neoadjuvant Toripalimab for Renal Cell Carcinoma: A Systematic Review Rananda, Arif; Haikal, Vikri; Oktavian, Puguh; Setyobudi, David; Kristanto, Roy Dwi Antariksa
Jurnal sosial dan sains Vol. 5 No. 11 (2025): Jurnal Sosial dan Sains
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/jurnalsosains.v5i11.32548

Abstract

Toripalimab, a programmed cell death protein-1 (PD-1) inhibitor, has emerged as a promising immunotherapy for renal cell carcinoma (RCC). This systematic review consolidates current evidence on the efficacy and safety of toripalimab-based regimens in RCC management. A systematic review was conducted following PRISMA guidelines and a pre-registered protocol (PROSPERO: CRD42021274404). Multiple databases and trial registries were searched from February 23, 2025. Six studies, including randomized controlled trials (RCTs), case-control studies, and case reports, were included for qualitative synthesis. The analysis demonstrated that toripalimab, particularly in combination with axitinib, significantly improved clinical outcomes compared to standard therapies like sunitinib. One major RCT reported a significant improvement in progression-free survival (PFS) (median 18.0 vs. 9.8 months) and a higher objective response rate (ORR) (56.7% vs. 30.8%). The combination also reduced the risk of disease progression or death by 35% (HR 0.65; 95% CI 0.49–0.86) and showed a significant overall survival (OS) benefit (HR 0.61; 95% CI 0.40–0.92). Favorable responses were also observed in challenging subgroups, including elderly patients and those with sarcomatoid RCC. Adverse events were consistent with known profiles of PD-1 and VEGFR inhibitors, including hypertension, hepatic enzyme elevation, and fatigue, and were generally manageable. Toripalimab-based regimens, especially in combination with axitinib, demonstrate significant improvements in PFS, ORR, and OS for patients with RCC, with a manageable safety profile. These findings support its potential as a valuable therapeutic option. However, further large-scale, multi-center studies with longer follow-up are warranted to confirm these findings.
Co-Authors Aflahudin, Muhammad Ahda Naufal Aulia, Shazia Hafazhah Farid, Muhammad Rifqo Hafidzudin Haikal, Vikri Hanani, Nadya Kelfinta Hariftyani, Arisvia Sukma Hewiz, Alya Shafira Kristanto, Roy Dwi Antariksa Musalim, Dian Anggraini Permatasari Oktavian, Puguh Rofiq, Rodia Amanata Setyobudi, David Sidqoh, Aida Badi’atus